Meeting
Abstract Number: 135
SHM Converge 2024
Background: Treating HFpEF (heart failure with preserved ejection fraction) is complex due to its diverse origins, leaving many patients with limited options. While diuretics offer symptom relief, most therapies don’t markedly improve outcomes. SGLT2 inhibitors, particularly Dapagliflozin, show potential in reducing cardiovascular events. Yet, guidelines for HFpEF and HFmrEF are vague regarding SGLT2 use. This […]
Abstract Number: 160
SHM Converge 2023
Background: The key goals of HF therapy are to prevent progression of symptoms, improve quality of life, and prolong survival. Studies have attempted to study and improve post hospitalization outcomes among patients with HF. Social determinants of Health include a wide set of factors from daily life which are responsible for health inequity. Burden of […]
Abstract Number: 170
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Heart failure (HF) and atrial fibrillation (AF) share several risk factors including coronary artery disease, hypertension, smoking, obesity, diabetes, and renal disease, as well as common pathophysiologic pathway involving activation of the renin–angiotensin–aldosterone system, maladaptive atrial remodeling and subsequent impaired conduction system. Some studies have supported the role of angiotensin converting enzyme inhibitors (ACEIs) […]